Drug Profile
Engedi 1000
Alternative Names: E 1K; Engedi1000Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Ensol Biosciences
- Class Analgesics; Antirheumatics; Peptides
- Mechanism of Action Nerve growth factor inhibitors; Smad protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 29 Nov 2023 Ensol Bioscience completes a phase II trial in Osteoarthritis (In adults, In the elderly) in South Korea (Intra-articular, Injection) (NCT05697952)
- 07 Sep 2022 Engedi 1000 is still in phase-I development in Osteoarthritis in South Korea (Intra-articular, Injection) (Ensol Biosciences pipeline, September 2022)
- 07 Sep 2022 Phase-II clinical trials in Osteoarthritis (In adults, In the elderly) in South Korea (Intra-articular, Injection) (NCT05697952) (Ensol Biosciences pipeline, September 2022)